Page 48 - 81_03
P. 48
conditional expression of a carboxyl-terminal Javier Gualix et al.
derivative of the ß-amyloid precursor protein. Brain
Res Mol Brain Res 1994; 26: 207-17. 47. Garcia-Guzman M, Soto F, Gomez-Hernandez JM,
Lund PE, Stuhmer W. Characterization of
33. Hyun DH, Lee M, Hattori N, et al. Effect of wild-type recombinant human P2X4 receptor reveals
or mutant Parkin on oxidative damage, nitric oxide, pharmacological differences to the rat homologue.
antioxidant defenses, and the proteasome. J Biol Mol Pharmacol 1997; 51: 109-18.
Chem 2002; 277: 28572-77.
48. Guo C, Masin M, Qureshi OS, Murrell-Lagnado RD.
34. Khakh BS, Proctor WR, Dunwiddie TV, Labarca C, Evidence for functional P2X4/P2X7 heteromeric
Lester HA. Allosteric control of gating and kinetics at receptors. Mol Pharmacol 2007; 72: 1447-56.
P2X4 receptor channels. J Neurosci 1999; 19: 7289-
99. 49. Le KT, Babinski K, Seguela P. Central P2X4 and P2X6
channel subunits coassemble into a novel heteromeric
35. Priel A, Silberberg SD. Mechanism of ivermectin ATP receptor. J Neurosci 1998; 18: 7152-59.
facilitation of human P2X4 receptor channels. J Gen
Physiol 2004; 123: 281-93. 50. Nicke A, Kerschensteiner D, Soto F. Biochemical and
functional evidence for heteromeric assembly of P2X1
36. von Kugelgen I. Pharmacological profiles of cloned and P2X4 subunits. J Neurochem 2005; 92: 925-33.
mammalian P2Y-receptor subtypes. Pharmacol Ther
2006; 110: 415-32. 51. Soto F, Garcia-Guzman M, Gomez-Hernandez JM,
Hollmann M, Karschin C, Stuhmer W. P2X4: an ATP-
37. Abbracchio MP, Burnstock G, Boeynaems JM, et al. activated ionotropic receptor cloned from rat brain.
International Union of Pharmacology LVIII: update Proc Natl Acad Sci USA 1996; 93: 3684-8.
on the P2Y G protein-coupled nucleotide receptors:
from molecular mechanisms and pathophysiology to 52. Bo X, Zhang Y, Nassar M, Burnstock G, Schoepfer R.
therapy. Pharmacol Rev 2006; 58: 281-341. A P2X purinoceptor cDNA conferring a novel
pharmacological profile. FEBS Lett 1995; 375: 129-
38. Marteau F, Le Poul E, Communi D, et al. 33.
Pharmacological characterization of the human P2Y13
receptor. Mol Pharmacol 2003; 64: 104-12. 53. Inoue K, Tsuda M, Koizumi S. ATP- and adenosine-
mediated signaling in the central nervous system:
39. Communi D, Gonzalez NS, Detheux M, et al. chronic pain and microglia: involvement of the ATP
Identification of a novel human ADP receptor coupled receptor P2X4. J Pharmacol Sci 2004; 94: 112-4.
to Gi. J Biol Chem 2001; 276: 41479-85.
54. Tsuda M, Shigemoto-Mogami Y, Koizumi S, et al.
40. Virginio C, Robertson G, Surprenant A, North RA. P2X4 receptors induced in spinal microglia gate tactile
Trinitrophenyl-substituted nucleotides are potent allodynia after nerve injury. Nature 2003; 424: 778-
antagonists selective for P2X1, P2X3, and heteromeric 83.
P2X2/3 receptors. Mol Pharmacol 1998; 53: 969-73.
55. Guo LH, Trautmann K, Schluesener HJ. Expression of
41. White PJ, Webb TE, Boarder MR. Characterization of P2X4 receptor by lesional activated microglia during
a Ca2+ response to both UTP and ATP at human P2Y11 formalin-induced inflammatory pain. J Neuroimmunol
receptors: evidence for agonist-specific signaling. Mol 2005; 163: 120-7.
Pharmacol 2003; 63: 1356-63.
56. Cavaliere F, Dinkel K, Reymann K. Microglia
42. Gever JR, Cockayne DA, Dillon MP, Burnstock G, response and P2 receptor participation in
Ford AP. Pharmacology of P2X channels. Pflugers oxygen/glucose deprivation-induced cortical damage.
Arch 2006; 452: 513-37. Neuroscience 2005; 136: 615-23.
43. Jones CA, Vial C, Sellers LA, Humphrey PP, Evans 57. Cavaliere F, Florenzano F, Amadio S, et al. Up-
RJ, Chessell IP. Functional regulation of P2X6 regulation of P2X2, P2X4 receptor and ischemic cell
receptors by N-linked glycosylation: identification of death: prevention by P2 antagonists. Neuroscience
a novel a,ß-methylene ATP-sensitive phenotype. Mol 2003; 120: 85-98.
Pharmacol 2004; 65: 979-85.
58. Sim JA, Chaumont S, Jo J, et al. Altered hippocampal
44. Evans RJ, Lewis C, Buell G, Valera S, North RA, synaptic potentiation in P2X4 knock-out mice. J
Surprenant A. Pharmacological characterization of Neurosci 2006; 26: 9006-9.
heterologously expressed ATP-gated cation channels
(P2x purinoceptors). Mol Pharmacol 1995; 48: 178- 59. Moore D, Chambers J, Waldvogel H, Faull R, Emson
83. P. Regional and cellular distribution of the P2Y1
purinergic receptor in the human brain: striking
45. Bo X, Jiang LH, Wilson HL, et al. Pharmacological neuronal localisation. J Comp Neurol 2000; 421: 374-
and biophysical properties of the human P2X5 84.
receptor. Mol Pharmacol 2003; 63: 1407-16.
60. Moore D, Iritani S, Chambers J, Emson P.
46. Rassendren F, Buell GN, Virginio C, Collo G, North Immunohistochemical localization of the P2Y1
RA, Surprenant A. The permeabilizing ATP receptor, purinergic receptor in Alzheimer's disease.
P2X7. Cloning and expression of a human cDNA. J Neuroreport 2000; 11: 3799-803.
Biol Chem 1997; 272: 5482-86.
61. Ecke D, Hanck T, Tulapurkar ME, et al. Hetero-
256 oligomerization of the P2Y11 receptor with the P2Y1
@Real Academia Nacional de Farmacia. Spain
